Hot Flushes
Conditions
Keywords
Estetrol, Vasomotor symptoms, Menopause
Brief summary
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
Detailed description
Oestrogen therapy is the most consistently effective treatment used in the US and Europe for menopausal VMS. Following the safety issues reported in the primary Women's Health Initiative publications and with continued subject requests for treatment, a challenge to clinicians has been to identify the lowest effective dose of oestrogen for alleviating menopausal symptoms. In addition, it is a challenge to develop a safer oestrogen than those currently used. For this purpose, the minimum effective dose (MED) of E4 has to be defined for the treatment of menopausal symptoms. The present study is intended to evaluate changes in frequency and in severity of moderate to severe VMS in order to define the MED. Subjects will be randomly allocated to either treatment group (2.5 mg E4, 5 mg E4, 10 mg E4, 15 mg E4, or placebo) in a 1:1:1:1:1 ratio. All treatments (E4 or Placebo) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Interventions
DRUGEstetrol
All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
DRUGPlacebo
1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Sponsors
SynteractHCR
Donesta Bioscience
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Women presenting at least 7 moderate to severe hot flushes/day or at least 50 moderate to severe hot flushes/week in the week preceding randomization. * Body Mass Index (BMI) between 18.0 and 35.0 kg/m², inclusive. * Post-menopausal status. * Intact uterus. * Negative pregnancy test. * Good physical and mental health. * Subject has provided signed and dated written informed consent before admission to the study. * Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.
Exclusion criteria
* Uterine disease or any medical conditions associated with an increase in endometrial thickness. * Any history of malignancy with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Any clinically significant findings at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer. * Abnormal cervical Pap smear. * Systolic blood pressure (BP) outside the range 90 to 140 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm. * Any clinically significant abnormality identified on the screening 12-lead ECG. * History of venous or arterial thromboembolic disease, history of known coagulopathy or abnormal coagulation factors. * Diabetes mellitus with poor glycaemic control. * Dyslipoproteinaemia at screening. * Smoking \>10 cigarettes/day. * Presence or history of gallbladder disease, unless cholecystectomy has been performed. * Systemic lupus erythematosus. * Multiple sclerosis. * Acute or chronic liver disease. * Acute or chronic renal impairment. * Uncontrolled thyroid disorders. * Use of oestrogen or progestin containing drug(s). * Use of non-hormonal treatments to reduce hot flushes. * History or presence of allergy or intolerance to any component of the investigational product. * History of alcohol or substance abuse or dependence in the 12 months before screening as determined by the Investigator. * Sponsor, CRO or Investigator's site personnel or their relatives directly affiliated with this study. * Subjects with known or suspected history of a clinically significant systemic diseases, unstable medical disorders, life-threatening disease or current malignancies that would pose a risk to the subject in the opinion of the Investigator. * Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to study entry. * Is judged by the Investigator to be unsuitable for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in weekly frequency of moderate to severe VMS from baseline to week 4. | From baseline to week 4 | — |
| Change in weekly frequency of moderate to severe VMS from baseline to week 12. | From baseline to week 12 | — |
| Change in severity of moderate to severe VMS from baseline to week 4. | From baseline to week 4 | The Severity Scoring System of VMS will be documented by the subjects by using the following scores: None (0) = No VMS symptoms; Mild (1) = Sensation of heat without sweating; Moderate (2) = Sensation of heat with sweating. Able to continue activity; Severe (3) = Sensation of heat with sweating. Causes cessation of activity. |
| Change in severity of moderate to severe VMS from baseline to week 12. | From baseline to week 12 | The Severity Scoring System of VMS will be documented by the subjects by using the following scores: None (0) = No VMS symptoms; Mild (1) = Sensation of heat without sweating; Moderate (2) = Sensation of heat with sweating. Able to continue activity; Severe (3) = Sensation of heat with sweating. Causes cessation of activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to week 12 in Vaginal Maturation Index (MI) (parabasal and superficial cells) | From baseline to week 12 | — |
| Serum concentration of triglycerides. | From baseline to week 12 | — |
| Serum concentration of low density lipoprotein (LDL)-cholesterol. | Baseline and Week 12 | — |
| Serum concentration of high density lipoprotein (HLD)-cholesterol. | Baseline and Week 12 | — |
| Serum concentration of total cholesterol. | Baseline and Week 12 | — |
| Fasting glycemia. | Baseline and Week 12 | — |
| Serum concentration of glycated hemoglobin. | Baseline and Week 12 | — |
| Homeostasis model assessment-estimated insulin resistance [HOMA-IR] | Baseline and Week 12 | — |
| Serum concentration of prothrombin fragment 1 + 2. | Baseline and Week 12 | — |
| Activated protein C sensitivity ratio (APCsr) (Endogenous Thrombin Potential [ETP]-Based). | Baseline and Week 12 | — |
| Serum concentration of D-dimers. | Baseline and Week 12 | — |
| Serum concentration of sex-hormone binding globulin (SHBG). | Baseline and Week 12 | — |
| Change from baseline to week 12 in genitourinary symptoms (GSM) of menopause | From baseline to week 12 | The following GSM symptoms will be evaluated: * Vaginal dryness (none, mild, moderate or severe) * Vaginal and/or vulvar irritation/itching (none, mild, moderate or severe) * Dysuria (none, mild, moderate or severe) * Vaginal pain associated with sexual activity (none, mild, moderate or severe) * Vaginal bleeding associated with sexual activity (presence vs. absence). |
| Serum concentration of protein-C. | Baseline and Week 12 | — |
| Serum concentration of free protein-S. | Baseline and Week 12 | — |
| Serum concentration of factor VIII. | Baseline and Week 12 | — |
| Serum concentration of free tissue factor pathway inhibitor [TFPI]. | Baseline and Week 12 | — |
| Serum concentration of osteocalcin. | Baseline and Week 12 | — |
| Serum concentration of C-terminal telopeptide [CTX-1] | Baseline and Week 12 | — |
| Percentage of subjects who had a change in endometrial thickness at each study visit. | From baseline to week 16 | — |
| Percentage of subjects with adverse events as a measure of safety and tolerability. | Up to week 16 | — |
| Maximum concentration (Cmax) of E4 in plasma. | Up to 90 days | — |
| Time to Cmax (Tmax) of E4 in plasma. | Up to 90 days | — |
| Terminal half-life (T1/2) of E4 in plasma. | Up to 90 days | — |
| Area under the plasma concentration-time curve from baseline to the last quantifiable concentration following dosing (AUCtau) of E4. | Up to 90 days | — |
| Serum concentration of antithrombin. | Baseline and Week 12 | — |
| Change in the Menopause Rating Scale (MRS) from baseline to week 5. | From baseline to week 5 | — |
| Change in the Menopause Rating Scale (MRS) from baseline to week 12. | From baseline to week 12 | — |
| Change from baseline to week 12 in Vaginal pH. | From baseline to week 12 | — |
Countries
Belgium
Outcome results
None listed